Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson’s Disease
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the Substantia Nigra pars compacta, leading to classical PD motor symptoms. Current therapies are purely symptomatic and do not modify disease progression. Cannabidiol (CBD), one of the main...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/16/8920 |
| _version_ | 1797523499710939136 |
|---|---|
| author | Claudio Giuliano Miriam Francavilla Gerardo Ongari Alessandro Petese Cristina Ghezzi Nora Rossini Fabio Blandini Silvia Cerri |
| author_facet | Claudio Giuliano Miriam Francavilla Gerardo Ongari Alessandro Petese Cristina Ghezzi Nora Rossini Fabio Blandini Silvia Cerri |
| author_sort | Claudio Giuliano |
| collection | DOAJ |
| description | Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the Substantia Nigra pars compacta, leading to classical PD motor symptoms. Current therapies are purely symptomatic and do not modify disease progression. Cannabidiol (CBD), one of the main phytocannabinoids identified in Cannabis Sativa, which exhibits a large spectrum of therapeutic properties, including anti-inflammatory and antioxidant effects, suggesting its potential as disease-modifying agent for PD. The aim of this study was to evaluate the effects of chronic treatment with CBD (10 mg/kg, i.p.) on PD-associated neurodegenerative and neuroinflammatory processes, and motor deficits in the 6-hydroxydopamine model. Moreover, we investigated the potential mechanisms by which CBD exerted its effects in this model. CBD-treated animals showed a reduction of nigrostriatal degeneration accompanied by a damping of the neuroinflammatory response and an improvement of motor performance. In particular, CBD exhibits a preferential action on astrocytes and activates the astrocytic transient receptor potential vanilloid 1 (TRPV1), thus, enhancing the endogenous neuroprotective response of ciliary neurotrophic factor (CNTF). These results overall support the potential therapeutic utility of CBD in PD, as both neuroprotective and symptomatic agent. |
| first_indexed | 2024-03-10T08:43:52Z |
| format | Article |
| id | doaj.art-6230e7f0a44a4006a5b3c2b918c19349 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T08:43:52Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-6230e7f0a44a4006a5b3c2b918c193492023-11-22T08:02:37ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-08-012216892010.3390/ijms22168920Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson’s DiseaseClaudio Giuliano0Miriam Francavilla1Gerardo Ongari2Alessandro Petese3Cristina Ghezzi4Nora Rossini5Fabio Blandini6Silvia Cerri7Unit of Cellular and Molecular Neurobiology, IRCCS Mondino Foundation, 27100 Pavia, ItalyUnit of Cellular and Molecular Neurobiology, IRCCS Mondino Foundation, 27100 Pavia, ItalyUnit of Cellular and Molecular Neurobiology, IRCCS Mondino Foundation, 27100 Pavia, ItalyUnit of Cellular and Molecular Neurobiology, IRCCS Mondino Foundation, 27100 Pavia, ItalyUnit of Cellular and Molecular Neurobiology, IRCCS Mondino Foundation, 27100 Pavia, ItalyLinnea SA, CH-6595 Riazzino, TI (CH), SwitzerlandUnit of Cellular and Molecular Neurobiology, IRCCS Mondino Foundation, 27100 Pavia, ItalyUnit of Cellular and Molecular Neurobiology, IRCCS Mondino Foundation, 27100 Pavia, ItalyParkinson’s disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the Substantia Nigra pars compacta, leading to classical PD motor symptoms. Current therapies are purely symptomatic and do not modify disease progression. Cannabidiol (CBD), one of the main phytocannabinoids identified in Cannabis Sativa, which exhibits a large spectrum of therapeutic properties, including anti-inflammatory and antioxidant effects, suggesting its potential as disease-modifying agent for PD. The aim of this study was to evaluate the effects of chronic treatment with CBD (10 mg/kg, i.p.) on PD-associated neurodegenerative and neuroinflammatory processes, and motor deficits in the 6-hydroxydopamine model. Moreover, we investigated the potential mechanisms by which CBD exerted its effects in this model. CBD-treated animals showed a reduction of nigrostriatal degeneration accompanied by a damping of the neuroinflammatory response and an improvement of motor performance. In particular, CBD exhibits a preferential action on astrocytes and activates the astrocytic transient receptor potential vanilloid 1 (TRPV1), thus, enhancing the endogenous neuroprotective response of ciliary neurotrophic factor (CNTF). These results overall support the potential therapeutic utility of CBD in PD, as both neuroprotective and symptomatic agent.https://www.mdpi.com/1422-0067/22/16/8920phytocannabinoidsneuroinflammationciliary neurotrophic factortransient receptor potential vanilloid 16-hydroxydopaminecannabidiol |
| spellingShingle | Claudio Giuliano Miriam Francavilla Gerardo Ongari Alessandro Petese Cristina Ghezzi Nora Rossini Fabio Blandini Silvia Cerri Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson’s Disease International Journal of Molecular Sciences phytocannabinoids neuroinflammation ciliary neurotrophic factor transient receptor potential vanilloid 1 6-hydroxydopamine cannabidiol |
| title | Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson’s Disease |
| title_full | Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson’s Disease |
| title_fullStr | Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson’s Disease |
| title_full_unstemmed | Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson’s Disease |
| title_short | Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson’s Disease |
| title_sort | neuroprotective and symptomatic effects of cannabidiol in an animal model of parkinson s disease |
| topic | phytocannabinoids neuroinflammation ciliary neurotrophic factor transient receptor potential vanilloid 1 6-hydroxydopamine cannabidiol |
| url | https://www.mdpi.com/1422-0067/22/16/8920 |
| work_keys_str_mv | AT claudiogiuliano neuroprotectiveandsymptomaticeffectsofcannabidiolinananimalmodelofparkinsonsdisease AT miriamfrancavilla neuroprotectiveandsymptomaticeffectsofcannabidiolinananimalmodelofparkinsonsdisease AT gerardoongari neuroprotectiveandsymptomaticeffectsofcannabidiolinananimalmodelofparkinsonsdisease AT alessandropetese neuroprotectiveandsymptomaticeffectsofcannabidiolinananimalmodelofparkinsonsdisease AT cristinaghezzi neuroprotectiveandsymptomaticeffectsofcannabidiolinananimalmodelofparkinsonsdisease AT norarossini neuroprotectiveandsymptomaticeffectsofcannabidiolinananimalmodelofparkinsonsdisease AT fabioblandini neuroprotectiveandsymptomaticeffectsofcannabidiolinananimalmodelofparkinsonsdisease AT silviacerri neuroprotectiveandsymptomaticeffectsofcannabidiolinananimalmodelofparkinsonsdisease |